By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Bâtiment Villejuif Bio Park
1 mail du Professeur Georges Mathé
  Villejuif  94800   France
Phone: 33-1-43-90-19-20 Fax: n/a



Company News
THERAVECTYS Secures Exclusive Access To A Synthetic Humanized Nanobody Library From Institut Curie And Strengthens Its Proprietary Immunotherapeutic Platform 4/14/2015 9:00:38 AM
THERAVECTYS to Hire Up to 25 As New French Manufacturing Plant Receives Approval 3/26/2015 4:52:52 PM
THERAVECTYS Granted Authorization By The French National Agency For Medicines To Produce Lentiviral Vectors For Clinical Use And CAR-T Cell Therapies Under GMP Standards 3/23/2015 10:21:07 AM
Delaware Court Finds That THERAVECTYS Is Reasonably Likely To Succeed On The Merits Of Its Tortious Interference Claim Against Immune Design Corporation (IMDZ) 3/11/2015 11:22:57 AM
THERAVECTYS Obtains Orphan Drug Designation From European Medicines Agency For Its Lentiviral Vector-Based Therapeutic Vaccine Against Adult T-Cell Leukemia And Lymphoma 2/5/2015 9:43:53 AM
THERAVECTYS Secures €1.9 Million From Bpifrance 1/26/2015 8:38:31 AM
THERAVECTYS Further Strengthens The Intellectual Property Of Its Lentiviral Vector Technology 12/3/2014 8:39:25 AM
THERAVECTYS Provides Update On Its Phase 1/2 Lentiviral Vector-Based Therapeutic Vaccine Trial 11/19/2014 12:03:04 PM
THERAVECTYS Files Suit In The U.S. Against Immune Design Corporation (IMDZ) 7/25/2014 9:10:42 AM
THERAVECTYS Finalizes The Recruitment Of Patients For The Phase I/II Clinical Trial Of Its Anti-HIV Therapeutic Vaccine Candidate 2/5/2014 5:58:41 AM